Table 3.
Median time from specimen collection to treatment initiation, by diagnostic method and disease classification (n = 686)
| Early cohort (n = 256) | Late cohort (n = 430) | P value | |
|---|---|---|---|
| Diagnosis method | |||
| Xpert MTB/RIF | 17 (9–46) (n = 107) | 13 (7–28) (n = 282) | < 0.001 |
| GenoType MTBDRplus line probe assay | 38 (23–51) (n = 129) | 15 (7–36) (n = 129) | |
| Phenotypic drug susceptibility testing | 81 (28–97) (n = 7) | n/a | |
| Disease classification | |||
| RR-TB by Xpert MTB/RIF | 13 (9–30) (n = 57) | 10 (7–17) (n = 188) | < 0.001 |
| RIF mono-resistant TB | 48 (30–75) (n = 48) | 13 (2–38) (n = 62) | |
| MDR-TB | 34 (14–49) (n = 147) | 22 (8–37) (n = 128) | |
| XDR-TB | 42 (35–70) (n = 3) | 36 (14–61) (n = 4) | |
MDR-TB Multi-drug resistant, XDR-TB Extensively drug resistant TB, RR-TB Rifampicin resistant TB, RIF rifampicin